Aurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new ...

Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq ...

Panelists highlight that oral endocrine therapies for hormone receptor-positive breast cancer are generally well tolerated ...

Aurobindo Pharma’s Dazublys, a trastuzumab biosimilar for HER2-positive cancers, gains EU approval, enhancing access to ...

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

US FDA clears Iksuda Therapeutics’ IND application for IKS014: New Castle, England Wednesday, July 2, 2025, 15:00 Hrs [IST] Iksuda Therapeutics, a clinical stage and UK-based bi ...

CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the "unfair" way they are ...